Insider Selling: Artivion (NYSE:AORT) SVP Sells 3,843 Shares of Stock

04 Mar 2026, 21:00 by Amy Steele · The Cerbat Gem

Artivion, Inc. (NYSE:AORT – Get Free Report) SVP Jean Holloway sold 3,843 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $145,188.54. Following the completion of the transaction, the senior vice president directly owned 194,057 shares in the company, valued at approximately $7,331,473.46. This trade represents a 1.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Artivion Trading Down 0.5%

NYSE:AORT traded down $0.21 during trading hours on Wednesday, reaching $38.41. 460,494 shares of the stock were exchanged, compared to its average volume of 509,518. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $48.25. The business has a 50-day moving average of $41.42 and a two-hundred day moving average of $42.92. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 61.30 and a beta of 1.60. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT – Get Free Report) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. The business’s quarterly revenue was up 19.2% compared to the same quarter last year. On average, equities analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Key Stories Impacting Artivion

Here are the key news stories impacting Artivion this week:

Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

Hedge Funds Weigh In On Artivion

Several hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its holdings in shares of Artivion by 107.0% in the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after buying an additional 20,010 shares in the last quarter. AQR Capital Management LLC lifted its position in Artivion by 8.8% in the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after acquiring an additional 2,823 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Artivion by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after acquiring an additional 1,032 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Artivion by 364.4% in the second quarter. Envestnet Asset Management Inc. now owns 52,871 shares of the company’s stock valued at $1,644,000 after acquiring an additional 41,487 shares in the last quarter. Finally, Atria Investments Inc purchased a new position in shares of Artivion during the second quarter worth about $244,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AORT has been the topic of several recent research reports. Canaccord Genuity Group cut their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Artivion in a research report on Friday, November 7th. Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Citizens Jmp upped their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Artivion currently has an average rating of “Moderate Buy” and an average target price of $48.97.

View Our Latest Stock Report on Artivion

About Artivion

(Get Free Report)

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.